Synonyms: F-2695 | Fetzima®
levomilnacipran is an approved drug (FDA (2013))
Compound class:
Synthetic organic
Comment: Levomilnacipran is the active enantiomer of milnacipran. [2]. It is a selective serotonin and norepinephrine reuptake inhibitor antidepressant (SNRI).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: levomilnacipran |
|
No information available. |
Summary of Clinical Use |
Used to treat major depressive disorder [1]. Clinical formulations contain levomilnacipran hydrochloride (PubChem CID 6917778). |
Mechanism Of Action and Pharmacodynamic Effects |
Levomilnacipran inhibits reuptake of serotonin and noradrenaline by their respective transporters, SERT (SLC6A4) and NET (SLC6A2). By inhibiting the re-uptake of serotonin and norepinephrine in the CNS, this drug rebalances the levels of these neurotransmitters and increases their activity. This improves symptoms of depression and anxiety. |
External links |
For extended ADME data see the following: Drugs.com |